# GSK Q3 2026 Earnings Report Highlights

> GSK reports 5% sales growth with specialty medicines driving momentum in Q3 2026.
- Title: GSK Q3 2026 Earnings Report Highlights · The Motley Fool
- Summary: GSK reports 5% sales growth with specialty medicines driving momentum in Q3 2026. GSK's Q3 2026 earnings show 5% sales growth at constant exchange rates…
- Keywords: gsk, q3 2026, earnings call, specialty medicines, core operating profit, r&d investment, cabenuva, shingrix, trelegy, hibsago, finance, money
- Source: The Motley Fool — https://fool.com/earnings/call-transcripts/2026/10/28/gsk-gsk-q3-2026-earnings-call-transcript
- Author: Motley Fool Transcribing
- Published: 2026-10-28T21:38:46+00:00
- Read time: 2 min
- Topics: gsk, q3 2026, earnings call, specialty medicines, core operating profit, r&d investment, cabenuva, shingrix, trelegy, hibsago, finance, money
## Q3 2026 Performance
GSK reported third-quarter revenue of GBP 8.9 billion, growing 5% at constant exchange rates.
## Specialty Medicines Growth
Specialty medicines revenue grew 15% at constant exchange rates, led by HIV and respiratory product performance.
## Cabenuva Performance
Cabenuva sales grew 35% during the quarter, with 75% of U.S. switches originating from competitor products.
## Exdensur Launch
Exdensur revenue reached GBP 27 million following its launch and availability of the J-code in July.
## Shingrix Performance
Shingrix performance declined 2% at constant exchange rates due to destocking in China.
## Trelegy Sales
Trelegy U.S. sales grew 8% as patients reached Medicare deductibles despite pricing pressures.
## Meningitis Portfolio
Meningitis portfolio rose 12% at constant exchange rates supported by back-to-school season for Penmenvy.
## Apretude Growth
Apretude growth rose 21% in the quarter, maintaining market share in HIV prevention segment.
## Nucala Revenue
Nucala revenue increased 18% at constant exchange rates driven by successful launch in COPD indication.
## Phase III Pipeline
18 phase III trial starts completed for 2026, including two new trials for influenza.
## Jideytro Launch
Jideytro sales reached GBP 3 million, representing first contribution from ROS1 positive nonsmall cell lung cancer treatment.
## Core EPS Growth
Core EPS grew 1% at constant exchange rates, impacted by increased interest costs and higher tax rate.
## Full-Year Interest Expense
Full-year interest expense guidance of GBP 700 million to GBP 750 million, including GBP 160 million for Nuvalent acquisition.
## Accelerate Growth Program
Accelerate Growth Program charges of GBP 0.3 billion in the quarter, with total 2026 charges expected up to GBP 1 billion.
## Cash Flow from Operations
Cash flow from operations reached GBP 7.4 billion year to date, representing a GBP 1.1 billion increase over prior year.
## Net Debt to Core EBITDA
Net debt to core EBITDA ratio remains at 1.8x, reflecting Nuvalent acquisition impact.
## Key takeaway

GSK's Q3 2026 earnings show 5% sales growth at constant exchange rates driven by specialty medicines, with core operating profit growing 5% and R&D investment up 22%.